Ultragenyx Pharmaceutical Inc. 13D and 13G filings for Arcturus Therapeutics Holdings Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-10-26 4:44 pm Sale |
2021-10-21 | 13D | Arcturus Therapeutics Holdings Inc. ARCT |
Ultragenyx Pharmaceutical Inc. RARE |
1,200,000 4.600% |
-200,000 (-14.29%) |
Filing |
| 2021-08-12 5:09 pm Sale |
2021-08-10 | 13D | Arcturus Therapeutics Holdings Inc. ARCT |
Ultragenyx Pharmaceutical Inc. RARE |
1,400,000 5.300% |
-800,000 (-36.36%) |
Filing |
| 2020-12-10 4:51 pm Sale |
2020-12-08 | 13D | Arcturus Therapeutics Holdings Inc. ARCT |
Ultragenyx Pharmaceutical Inc. RARE |
2,200,000 9.000% |
-800,000 (-26.67%) |
Filing |
| 2020-05-22 5:21 pm Purchase |
2020-05-20 | 13D | Arcturus Therapeutics Holdings Inc. ARCT |
Ultragenyx Pharmaceutical Inc. RARE |
3,000,000 14.600% |
321,964 (+12.02%) |
Filing |